Multi-Modality Management of Stage IV Melanoma in the Era of Immunotherapy

Released On
June 18, 2019

Expires On
June 18, 2020

Media Type
Internet

Completion Time
60 minutes

Specialty
Oncology

Topic(s)
Melanoma

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Society of Surgical Oncology (SSO).

 

This activity is partially supported by independent educational grants from Merck, Amgen and Bristol-Myers-Squibb.

 

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for all surgeons and other health care professionals who are involved in the treatment of patients with melanoma.

Program Overview

Recent clinical trials suggest new options for neoadjuvant and adjuvant treatments for advanced melanoma. Surgical oncologists need to become familiar with these data to provide optimal treatment to their patients. This webinar is based on the SSO 2019 session.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the mechanisms of action and toxicities of novel immunotherapeutic agents for metastatic melanoma
  • Integrate novel immunotherapeutic agents for metastatic melanoma in combination with surgery
  • Identify new agents likely to be approved for use in metastatic melanoma

Faculty

Genvieve Boland, MD, PhD (Speaker)

Weill Cornelll Medicine

Mark Faries, MD (Speaker)

Cedars-Sinai Medical Center

Omid Hamid, MD (Speaker)

The Angeles Clinic and Research Institute

Accreditation Statement

The Society of Surgical Oncology (SSO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation

The Society of Surgical Oncology designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The SSO has approved this activity for up to 1 self-assessment credit which meets the requirement of the self¬-assessment component of the American Board of Surgery (ABS) Continuous Certification Program.

Disclosures of Conflicts of Interest

In accordance with the ACCME’s Accreditation Criteria, the Society of Surgical Oncology must ensure that anyone in position to control the content of this educational activity has disclosed all financial relationships with a commercial interest. All educational planners, authors, reviewers, and other individuals in a position to control or influence the content of this activity were required to disclose all financial relationships with any commercial interest that have occurred within the past 12 months. This includes the disclosure of financial relationships of a spouse or partner. The ACCME considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of CME about the products or services of that commercial interest. The ACCME defines a commercial interest as “any entity producing, marketing, reselling, or distributing health care goods or services consumed by, or used on, patients.” ACCME does not consider providers of clinical service directly to patients to be commercial interests.

The ACCME also requires that the Society of Surgical Oncology resolve any reported conflict of interest and ensure the educational content of this activity is vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. If you perceive bias while participating in this activity, please advise us of the circumstances when completing your postactivity evaluation form.

All identified conflicts of interests have been resolved.

Genevieve M Boland, MD, PhD (Faculty/Planner)

  • Grant/Research: Takeda Oncology (Sponsored research agreement)

Mark Faries, MD (Faculty/Planner)

  • Consultant: Delcath Systems, Inc
  • Advisory Board: Pulse Bioscience, Inc

Omid Hamid, MD (Faculty/Planner)

  • Consultant and Advisory Board: Amgen, Novartis, Roche Genentech, BMS, Merck
  • Speaker Honoraria: BMS, Genentech Roche, Novartis, Amgen, Array Biopharma
  • Research/Contracted Research for Institution: Astra Zeneca, BMS, Celldex, Genentech Roche, Immunocore, Incyte, Merck, Merck Serano, MedImmune, Novartis, Pfizer, Rinnat

Planners, Reviewers, and Staff

Dale Han, MD, CME/CPD Committee Reviewer, has disclosed no relevant financial relationships.

Alanna Persaud, Program Manager, Society of Surgical Oncology, has disclosed no relevant financial relationships.

Kelley Gazer, Education Coordinator, Society of Surgical Oncology, has disclosed no relevant financial relationships.

Requirements for Earning Credit and Method of Participation

This online activity consists of a webinar, a self-assessment exam, and an evaluation. To receive AMA PRA Category 1 Credit™ and self-assessment credit, participants must watch the webinar, successfully complete the self-assessment exam, and achieve a minimum score of 75% on the exam. The self-assessment exam includes 4 multiple choice questions. Learners will be asked to read each question, select an answer, and review the section of the webinar where the answer is found. Learners will be able to review the content and repeat the self-assessment exam as many times as needed. Upon achieving a score of 75% or higher, learners will be asked to complete a postactivity evaluation. A certificate of credit will be available upon successful submission of the post-activity evaluation.

Disclosure of Unlabeled Use

This educational activity may include discussions of unlabeled/unapproved uses of drugs or devices. Participants are advised to refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Opinions expressed in this educational activity are those of the expert contributors and do not necessarily represent the views of the Society of Surgical Oncology or any other organization associated with this activity.

Privacy and Confidentiality

For information about the Society of Surgical Oncology’s privacy policy and associated disclaimer, please visit this site: http://www.surgonc.org/disclaimer.

Course Viewing Requirements

Computer Specifications
Bandwidth: 512kbps
Required Hardware and Software: Screen resolution of 1024X768 or larger, Sound card and speakers/headphones
512MB of RAM

Operating System
Windows: Windows 7; Windows Vista; Windows XP Service Pack 2 or 3 with X86 or x64 (Browsers must be in 32-bit mode) 1.6-gigahertz (GHz) or higher processor
Mac OS: Apple Mac OS X 10.4.8 or above with Intel Core™ Duo 1.83GHz or faster processor

Supported Browsers:
Microsoft Internet Explorer 7.0+ or better
Mozilla Firefox 4 or better
Safari 5 or better

Supported Phones & Tablets:
Android 2.3+ with Adobe Flash Player 10.2 or better installed
Apple devices with iOS 4+

For technical support, please contact us

Disclaimer

The primary purpose of the Society of Surgical Oncology's enduring material is educational. Information, as well as technologies, products, and/or services, discussed are intended to inform participants about the knowledge, techniques, and experiences of specialists who are willing to share such information with colleagues. A diversity of professional opinions exists in the specialty, and the Society of Surgical Oncology disclaims any and all liability for damages to any individual using the materials and for all claims which may result from the use of information, technologies, products, and/or services discussed.